U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299422) titled 'A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus' on Nov. 28.
Brief Summary: This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
DRUG: SHR-2...